ALS Drug Relyvrio Fails Critical Phase III Trial, Putting Access at Risk – Major Setback for Amylyx
Boston, MA – Amylyx’s hopes of revolutionizing the treatment of ALS with their FDA-approved drug, Relivrio, have been dashed as the drug failed a critical Phase III trial. The disappointing results, revealed on Friday, have cast doubt on the future availability of this potential treatment for the devastating neurodegenerative disease. The failure of Relivrio to outperform a placebo in a Phase III trial involving 664 ALS patients has sent shockwaves through the medical community. Not …